Clinical Trials Browser

Phase 2 × rolapitant × CNS × Clear all

NCT02991456 2023-07-11

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

Phase 2 Completed

48 enrolled 25 charts

Glioma, Nausea, Vomiting